Ombitasvir plus paritaprevir plus ritonavir with or without ribavirin in treatment-naive and treatment-experienced patients with genotype 4 chronic hepatitis C virus infection (PEARL-I): a randomised, open-label trial
Publication Type:
Journal Article
Authors:
Christophe Hézode;
Asselah, T.;
K R Reddy;
Hassanein, T.;
Berenguer, M.;
Fleischer-Stepniewska, K.;
P. Marcellin;
Hall, C.;
Schnell, G.;
Pilot-Matias, T.;
Mobashery, N.;
Redman, R.;
Vilchez, R.A.;
Stanislas PolSource:
Lancet, Volume 385, Issue 9986, p.2502-2509 (2015)
Keywords:
Aged,
analysis,
California,
Chicago,
chronic HCV,
deficiency,
Disease,
France,
Gastroenterology,
Genotype,
HCV,
Headache,
hepatitis,
Hepatitis C,
hepatitis C virus,
Hospitals,
Infection,
Intention,
interferon,
Interruption,
Italy,
Liver,
Liver Diseases,
medication,
methods,
NS5A inhibitor,
Paris,
Patients,
pegylated,
pegylated interferon,
Philadelphia,
Plasma,
protease inhibitor,
Research,
Ribavirin,
ritonavir,
Rna,
Safety,
Spain,
treatment,
treatment-naive,
Turkey,
Universities
